nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Imiquimod—skin cancer	0.0916	0.186	CbGbCtD
Ziprasidone—CYP1A2—Vemurafenib—skin cancer	0.0502	0.102	CbGbCtD
Ziprasidone—CYP3A4—Imiquimod—skin cancer	0.048	0.0972	CbGbCtD
Ziprasidone—CYP3A4—Temozolomide—skin cancer	0.048	0.0972	CbGbCtD
Ziprasidone—CYP2D6—Vemurafenib—skin cancer	0.0414	0.0838	CbGbCtD
Ziprasidone—CYP1A2—Dacarbazine—skin cancer	0.0385	0.0779	CbGbCtD
Ziprasidone—CYP3A4—Vismodegib—skin cancer	0.0333	0.0674	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0309	0.0625	CbGbCtD
Ziprasidone—CYP3A7—Docetaxel—skin cancer	0.0309	0.0625	CbGbCtD
Ziprasidone—CYP3A4—Vemurafenib—skin cancer	0.0263	0.0533	CbGbCtD
Ziprasidone—CYP3A5—Docetaxel—skin cancer	0.0231	0.0469	CbGbCtD
Ziprasidone—CYP1A2—Fluorouracil—skin cancer	0.0226	0.0457	CbGbCtD
Ziprasidone—DRD5—eyelid—skin cancer	0.0165	0.137	CbGeAlD
Ziprasidone—CYP3A4—Docetaxel—skin cancer	0.00903	0.0183	CbGbCtD
Ziprasidone—CHRM3—muscle of abdomen—skin cancer	0.00709	0.0589	CbGeAlD
Ziprasidone—HRH1—nose—skin cancer	0.00548	0.0455	CbGeAlD
Ziprasidone—CHRM5—skin epidermis—skin cancer	0.00463	0.0385	CbGeAlD
Ziprasidone—DRD1—nerve—skin cancer	0.00336	0.0279	CbGeAlD
Ziprasidone—HTR3A—nerve—skin cancer	0.00325	0.027	CbGeAlD
Ziprasidone—H1F0—hair follicle—skin cancer	0.00285	0.0237	CbGeAlD
Ziprasidone—HTR2A—hindlimb—skin cancer	0.00216	0.0179	CbGeAlD
Ziprasidone—HTR1B—blood vessel—skin cancer	0.00214	0.0178	CbGeAlD
Ziprasidone—HTR7—nerve—skin cancer	0.0021	0.0174	CbGeAlD
Ziprasidone—HTR1D—blood vessel—skin cancer	0.00207	0.0172	CbGeAlD
Ziprasidone—DRD2—nerve—skin cancer	0.00199	0.0165	CbGeAlD
Ziprasidone—H1F0—nipple—skin cancer	0.00193	0.0161	CbGeAlD
Ziprasidone—H1F0—neck—skin cancer	0.00191	0.0159	CbGeAlD
Ziprasidone—HTR2A—appendage—skin cancer	0.00185	0.0153	CbGeAlD
Ziprasidone—HTR7—endothelium—skin cancer	0.00179	0.0149	CbGeAlD
Ziprasidone—HTR7—blood vessel—skin cancer	0.00165	0.0137	CbGeAlD
Ziprasidone—CHRM5—epithelium—skin cancer	0.00151	0.0125	CbGeAlD
Ziprasidone—CHRM5—skin of body—skin cancer	0.00144	0.0119	CbGeAlD
Ziprasidone—H1F0—connective tissue—skin cancer	0.00137	0.0114	CbGeAlD
Ziprasidone—HTR1E—head—skin cancer	0.00137	0.0113	CbGeAlD
Ziprasidone—HTR2A—nerve—skin cancer	0.00131	0.0109	CbGeAlD
Ziprasidone—DRD5—lymphoid tissue—skin cancer	0.0013	0.0108	CbGeAlD
Ziprasidone—DRD5—female reproductive system—skin cancer	0.00125	0.0104	CbGeAlD
Ziprasidone—H1F0—skin of body—skin cancer	0.00124	0.0103	CbGeAlD
Ziprasidone—CHRM4—head—skin cancer	0.0012	0.00995	CbGeAlD
Ziprasidone—HTR7—neck—skin cancer	0.00118	0.0098	CbGeAlD
Ziprasidone—H1F0—mammalian vulva—skin cancer	0.00113	0.00937	CbGeAlD
Ziprasidone—HTR2A—endothelium—skin cancer	0.00112	0.00926	CbGeAlD
Ziprasidone—DRD3—head—skin cancer	0.00111	0.00925	CbGeAlD
Ziprasidone—KCNH2—nipple—skin cancer	0.00111	0.00923	CbGeAlD
Ziprasidone—ADRA2C—nipple—skin cancer	0.0011	0.0091	CbGeAlD
Ziprasidone—HTR6—head—skin cancer	0.00107	0.0089	CbGeAlD
Ziprasidone—HTR1D—connective tissue—skin cancer	0.00106	0.00882	CbGeAlD
Ziprasidone—DRD5—head—skin cancer	0.00104	0.00867	CbGeAlD
Ziprasidone—HTR2A—blood vessel—skin cancer	0.00103	0.00854	CbGeAlD
Ziprasidone—H1F0—lymphoid tissue—skin cancer	0.001	0.00832	CbGeAlD
Ziprasidone—H1F0—female reproductive system—skin cancer	0.000967	0.00803	CbGeAlD
Ziprasidone—CYP1A2—nipple—skin cancer	0.000952	0.0079	CbGeAlD
Ziprasidone—CHRM5—head—skin cancer	0.000937	0.00778	CbGeAlD
Ziprasidone—HRH1—nipple—skin cancer	0.000891	0.0074	CbGeAlD
Ziprasidone—ADRA2A—nipple—skin cancer	0.000875	0.00726	CbGeAlD
Ziprasidone—ADRA1B—head—skin cancer	0.000856	0.00711	CbGeAlD
Ziprasidone—HTR7—connective tissue—skin cancer	0.000846	0.00702	CbGeAlD
Ziprasidone—H1F0—head—skin cancer	0.000808	0.00671	CbGeAlD
Ziprasidone—HTR7—epithelium—skin cancer	0.000803	0.00667	CbGeAlD
Ziprasidone—DRD1—head—skin cancer	0.000798	0.00662	CbGeAlD
Ziprasidone—ADRA1A—epithelium—skin cancer	0.000775	0.00643	CbGeAlD
Ziprasidone—HTR1B—female reproductive system—skin cancer	0.000774	0.00642	CbGeAlD
Ziprasidone—HTR3A—head—skin cancer	0.000771	0.0064	CbGeAlD
Ziprasidone—HTR1D—female reproductive system—skin cancer	0.000749	0.00622	CbGeAlD
Ziprasidone—HTR2C—female reproductive system—skin cancer	0.000742	0.00616	CbGeAlD
Ziprasidone—HTR2A—neck—skin cancer	0.000736	0.00611	CbGeAlD
Ziprasidone—SLC6A4—female reproductive system—skin cancer	0.000703	0.00584	CbGeAlD
Ziprasidone—CHRM1—female reproductive system—skin cancer	0.000701	0.00582	CbGeAlD
Ziprasidone—HTR1B—head—skin cancer	0.000647	0.00537	CbGeAlD
Ziprasidone—CHRM2—head—skin cancer	0.000643	0.00534	CbGeAlD
Ziprasidone—ADRA2C—mammalian vulva—skin cancer	0.000641	0.00532	CbGeAlD
Ziprasidone—HRH1—connective tissue—skin cancer	0.000632	0.00524	CbGeAlD
Ziprasidone—CHRM3—female reproductive system—skin cancer	0.000627	0.0052	CbGeAlD
Ziprasidone—HTR1D—head—skin cancer	0.000626	0.0052	CbGeAlD
Ziprasidone—ADRA2A—connective tissue—skin cancer	0.000621	0.00515	CbGeAlD
Ziprasidone—HTR2C—head—skin cancer	0.00062	0.00515	CbGeAlD
Ziprasidone—HRH1—epithelium—skin cancer	0.0006	0.00498	CbGeAlD
Ziprasidone—ADRA1A—lymphoid tissue—skin cancer	0.000597	0.00495	CbGeAlD
Ziprasidone—HTR7—female reproductive system—skin cancer	0.000597	0.00495	CbGeAlD
Ziprasidone—SLC6A4—head—skin cancer	0.000588	0.00488	CbGeAlD
Ziprasidone—CHRM1—head—skin cancer	0.000585	0.00486	CbGeAlD
Ziprasidone—H1F0—lymph node—skin cancer	0.000566	0.0047	CbGeAlD
Ziprasidone—KCNH2—female reproductive system—skin cancer	0.000556	0.00462	CbGeAlD
Ziprasidone—HTR2A—connective tissue—skin cancer	0.000528	0.00438	CbGeAlD
Ziprasidone—CHRM3—head—skin cancer	0.000524	0.00435	CbGeAlD
Ziprasidone—HTR1A—head—skin cancer	0.000522	0.00433	CbGeAlD
Ziprasidone—HRH1—mammalian vulva—skin cancer	0.00052	0.00432	CbGeAlD
Ziprasidone—ADRA2A—mammalian vulva—skin cancer	0.000511	0.00424	CbGeAlD
Ziprasidone—HTR2A—epithelium—skin cancer	0.000501	0.00416	CbGeAlD
Ziprasidone—HTR7—head—skin cancer	0.000499	0.00414	CbGeAlD
Ziprasidone—ADRA1A—head—skin cancer	0.000481	0.00399	CbGeAlD
Ziprasidone—DRD2—head—skin cancer	0.000471	0.00391	CbGeAlD
Ziprasidone—KCNH2—head—skin cancer	0.000464	0.00386	CbGeAlD
Ziprasidone—ADRA2C—head—skin cancer	0.000458	0.0038	CbGeAlD
Ziprasidone—HRH1—female reproductive system—skin cancer	0.000446	0.0037	CbGeAlD
Ziprasidone—ADRA2A—female reproductive system—skin cancer	0.000438	0.00363	CbGeAlD
Ziprasidone—HRH1—head—skin cancer	0.000372	0.00309	CbGeAlD
Ziprasidone—HTR2A—female reproductive system—skin cancer	0.000372	0.00309	CbGeAlD
Ziprasidone—ADRA2A—head—skin cancer	0.000366	0.00304	CbGeAlD
Ziprasidone—Epistaxis—Fluorouracil—skin cancer	0.00036	0.00113	CcSEcCtD
Ziprasidone—Hyponatraemia—Docetaxel—skin cancer	0.000359	0.00113	CcSEcCtD
Ziprasidone—Visual impairment—Temozolomide—skin cancer	0.000358	0.00113	CcSEcCtD
Ziprasidone—Erythema—Dactinomycin—skin cancer	0.000358	0.00113	CcSEcCtD
Ziprasidone—Pain in extremity—Docetaxel—skin cancer	0.000357	0.00112	CcSEcCtD
Ziprasidone—Anaemia—Bleomycin—skin cancer	0.000354	0.00112	CcSEcCtD
Ziprasidone—Diarrhoea—Vemurafenib—skin cancer	0.000353	0.00111	CcSEcCtD
Ziprasidone—Urticaria—Imiquimod—skin cancer	0.00035	0.0011	CcSEcCtD
Ziprasidone—Body temperature increased—Imiquimod—skin cancer	0.000348	0.0011	CcSEcCtD
Ziprasidone—Abdominal pain—Imiquimod—skin cancer	0.000348	0.0011	CcSEcCtD
Ziprasidone—Eye disorder—Temozolomide—skin cancer	0.000347	0.00109	CcSEcCtD
Ziprasidone—Tinnitus—Temozolomide—skin cancer	0.000346	0.00109	CcSEcCtD
Ziprasidone—Cardiac disorder—Temozolomide—skin cancer	0.000345	0.00109	CcSEcCtD
Ziprasidone—CYP3A4—female reproductive system—skin cancer	0.000345	0.00286	CbGeAlD
Ziprasidone—Haemoglobin—Fluorouracil—skin cancer	0.000344	0.00108	CcSEcCtD
Ziprasidone—Leukopenia—Bleomycin—skin cancer	0.000343	0.00108	CcSEcCtD
Ziprasidone—Rhinitis—Fluorouracil—skin cancer	0.000343	0.00108	CcSEcCtD
Ziprasidone—Haemorrhage—Fluorouracil—skin cancer	0.000342	0.00108	CcSEcCtD
Ziprasidone—Dizziness—Vemurafenib—skin cancer	0.000342	0.00108	CcSEcCtD
Ziprasidone—Hypoaesthesia—Fluorouracil—skin cancer	0.000341	0.00107	CcSEcCtD
Ziprasidone—Pharyngitis—Fluorouracil—skin cancer	0.00034	0.00107	CcSEcCtD
Ziprasidone—CYP2D6—female reproductive system—skin cancer	0.000339	0.00281	CbGeAlD
Ziprasidone—Angiopathy—Temozolomide—skin cancer	0.000337	0.00106	CcSEcCtD
Ziprasidone—Ataxia—Docetaxel—skin cancer	0.000336	0.00106	CcSEcCtD
Ziprasidone—Immune system disorder—Temozolomide—skin cancer	0.000336	0.00106	CcSEcCtD
Ziprasidone—Mediastinal disorder—Temozolomide—skin cancer	0.000335	0.00105	CcSEcCtD
Ziprasidone—Cough—Bleomycin—skin cancer	0.000335	0.00105	CcSEcCtD
Ziprasidone—Chills—Temozolomide—skin cancer	0.000333	0.00105	CcSEcCtD
Ziprasidone—Dehydration—Docetaxel—skin cancer	0.000332	0.00105	CcSEcCtD
Ziprasidone—Anaemia—Dactinomycin—skin cancer	0.000331	0.00104	CcSEcCtD
Ziprasidone—Liver function test abnormal—Docetaxel—skin cancer	0.00033	0.00104	CcSEcCtD
Ziprasidone—Vomiting—Vemurafenib—skin cancer	0.000328	0.00103	CcSEcCtD
Ziprasidone—Alopecia—Temozolomide—skin cancer	0.000328	0.00103	CcSEcCtD
Ziprasidone—Myalgia—Bleomycin—skin cancer	0.000326	0.00103	CcSEcCtD
Ziprasidone—Chest pain—Bleomycin—skin cancer	0.000326	0.00103	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Docetaxel—skin cancer	0.000326	0.00103	CcSEcCtD
Ziprasidone—Rash—Vemurafenib—skin cancer	0.000326	0.00103	CcSEcCtD
Ziprasidone—Mental disorder—Temozolomide—skin cancer	0.000326	0.00102	CcSEcCtD
Ziprasidone—Dermatitis—Vemurafenib—skin cancer	0.000325	0.00102	CcSEcCtD
Ziprasidone—KCNH2—lymph node—skin cancer	0.000325	0.0027	CbGeAlD
Ziprasidone—Hypersensitivity—Imiquimod—skin cancer	0.000325	0.00102	CcSEcCtD
Ziprasidone—Headache—Vemurafenib—skin cancer	0.000324	0.00102	CcSEcCtD
Ziprasidone—Erythema—Temozolomide—skin cancer	0.000323	0.00102	CcSEcCtD
Ziprasidone—Malnutrition—Temozolomide—skin cancer	0.000323	0.00102	CcSEcCtD
Ziprasidone—Breast disorder—Docetaxel—skin cancer	0.000323	0.00102	CcSEcCtD
Ziprasidone—Cramp muscle—Docetaxel—skin cancer	0.000322	0.00101	CcSEcCtD
Ziprasidone—ADRA2C—lymph node—skin cancer	0.000321	0.00266	CbGeAlD
Ziprasidone—Leukopenia—Dactinomycin—skin cancer	0.00032	0.00101	CcSEcCtD
Ziprasidone—Nasopharyngitis—Docetaxel—skin cancer	0.000319	0.00101	CcSEcCtD
Ziprasidone—Asthenia—Imiquimod—skin cancer	0.000316	0.000995	CcSEcCtD
Ziprasidone—Confusional state—Bleomycin—skin cancer	0.000316	0.000993	CcSEcCtD
Ziprasidone—Back pain—Temozolomide—skin cancer	0.000313	0.000985	CcSEcCtD
Ziprasidone—HTR2A—head—skin cancer	0.000311	0.00258	CbGeAlD
Ziprasidone—Infection—Bleomycin—skin cancer	0.000311	0.000978	CcSEcCtD
Ziprasidone—Dysphagia—Docetaxel—skin cancer	0.000309	0.000972	CcSEcCtD
Ziprasidone—Nausea—Vemurafenib—skin cancer	0.000307	0.000966	CcSEcCtD
Ziprasidone—Thrombocytopenia—Bleomycin—skin cancer	0.000306	0.000964	CcSEcCtD
Ziprasidone—Arrhythmia—Fluorouracil—skin cancer	0.000306	0.000963	CcSEcCtD
Ziprasidone—Vision blurred—Temozolomide—skin cancer	0.000305	0.000959	CcSEcCtD
Ziprasidone—Myalgia—Dactinomycin—skin cancer	0.000304	0.000958	CcSEcCtD
Ziprasidone—Tremor—Temozolomide—skin cancer	0.000303	0.000954	CcSEcCtD
Ziprasidone—Alopecia—Fluorouracil—skin cancer	0.000303	0.000952	CcSEcCtD
Ziprasidone—Diarrhoea—Imiquimod—skin cancer	0.000301	0.000949	CcSEcCtD
Ziprasidone—Angina pectoris—Docetaxel—skin cancer	0.000301	0.000946	CcSEcCtD
Ziprasidone—Anaemia—Temozolomide—skin cancer	0.000299	0.000941	CcSEcCtD
Ziprasidone—Anorexia—Bleomycin—skin cancer	0.000298	0.000939	CcSEcCtD
Ziprasidone—Erythema—Fluorouracil—skin cancer	0.000298	0.000938	CcSEcCtD
Ziprasidone—Agitation—Temozolomide—skin cancer	0.000297	0.000936	CcSEcCtD
Ziprasidone—Angioedema—Temozolomide—skin cancer	0.000296	0.00093	CcSEcCtD
Ziprasidone—Hypotension—Bleomycin—skin cancer	0.000292	0.00092	CcSEcCtD
Ziprasidone—Dizziness—Imiquimod—skin cancer	0.000291	0.000917	CcSEcCtD
Ziprasidone—Vertigo—Temozolomide—skin cancer	0.000291	0.000915	CcSEcCtD
Ziprasidone—Infection—Dactinomycin—skin cancer	0.00029	0.000913	CcSEcCtD
Ziprasidone—Leukopenia—Temozolomide—skin cancer	0.00029	0.000911	CcSEcCtD
Ziprasidone—Palpitations—Temozolomide—skin cancer	0.000286	0.0009	CcSEcCtD
Ziprasidone—Thrombocytopenia—Dactinomycin—skin cancer	0.000286	0.000899	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000285	0.000897	CcSEcCtD
Ziprasidone—CYP2D6—head—skin cancer	0.000283	0.00235	CbGeAlD
Ziprasidone—Cough—Temozolomide—skin cancer	0.000282	0.000888	CcSEcCtD
Ziprasidone—Paraesthesia—Bleomycin—skin cancer	0.000281	0.000884	CcSEcCtD
Ziprasidone—Weight increased—Docetaxel—skin cancer	0.000281	0.000884	CcSEcCtD
Ziprasidone—Vision blurred—Fluorouracil—skin cancer	0.000281	0.000884	CcSEcCtD
Ziprasidone—Vomiting—Imiquimod—skin cancer	0.00028	0.000881	CcSEcCtD
Ziprasidone—Weight decreased—Docetaxel—skin cancer	0.000279	0.000879	CcSEcCtD
Ziprasidone—Hypertension—Temozolomide—skin cancer	0.000279	0.000879	CcSEcCtD
Ziprasidone—Dyspnoea—Bleomycin—skin cancer	0.000279	0.000878	CcSEcCtD
Ziprasidone—Anorexia—Dactinomycin—skin cancer	0.000278	0.000876	CcSEcCtD
Ziprasidone—Rash—Imiquimod—skin cancer	0.000278	0.000874	CcSEcCtD
Ziprasidone—Dermatitis—Imiquimod—skin cancer	0.000277	0.000873	CcSEcCtD
Ziprasidone—Pneumonia—Docetaxel—skin cancer	0.000277	0.000871	CcSEcCtD
Ziprasidone—Headache—Imiquimod—skin cancer	0.000276	0.000869	CcSEcCtD
Ziprasidone—Anaemia—Fluorouracil—skin cancer	0.000275	0.000867	CcSEcCtD
Ziprasidone—Arthralgia—Temozolomide—skin cancer	0.000275	0.000867	CcSEcCtD
Ziprasidone—Myalgia—Temozolomide—skin cancer	0.000275	0.000867	CcSEcCtD
Ziprasidone—Infestation—Docetaxel—skin cancer	0.000275	0.000866	CcSEcCtD
Ziprasidone—Infestation NOS—Docetaxel—skin cancer	0.000275	0.000866	CcSEcCtD
Ziprasidone—Anxiety—Temozolomide—skin cancer	0.000274	0.000864	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000273	0.000861	CcSEcCtD
Ziprasidone—Decreased appetite—Bleomycin—skin cancer	0.000272	0.000856	CcSEcCtD
Ziprasidone—Renal failure—Docetaxel—skin cancer	0.000271	0.000852	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Docetaxel—skin cancer	0.00027	0.000849	CcSEcCtD
Ziprasidone—Dry mouth—Temozolomide—skin cancer	0.000269	0.000848	CcSEcCtD
Ziprasidone—Jaundice—Docetaxel—skin cancer	0.000268	0.000844	CcSEcCtD
Ziprasidone—Conjunctivitis—Docetaxel—skin cancer	0.000268	0.000842	CcSEcCtD
Ziprasidone—Leukopenia—Fluorouracil—skin cancer	0.000267	0.00084	CcSEcCtD
Ziprasidone—Confusional state—Temozolomide—skin cancer	0.000266	0.000838	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000266	0.000837	CcSEcCtD
Ziprasidone—Infection—Temozolomide—skin cancer	0.000262	0.000825	CcSEcCtD
Ziprasidone—Nausea—Imiquimod—skin cancer	0.000262	0.000823	CcSEcCtD
Ziprasidone—HRH1—lymph node—skin cancer	0.000261	0.00216	CbGeAlD
Ziprasidone—Epistaxis—Docetaxel—skin cancer	0.00026	0.000817	CcSEcCtD
Ziprasidone—Nervous system disorder—Temozolomide—skin cancer	0.000259	0.000815	CcSEcCtD
Ziprasidone—Thrombocytopenia—Temozolomide—skin cancer	0.000258	0.000813	CcSEcCtD
Ziprasidone—Feeling abnormal—Bleomycin—skin cancer	0.000258	0.000812	CcSEcCtD
Ziprasidone—Skin disorder—Temozolomide—skin cancer	0.000256	0.000807	CcSEcCtD
Ziprasidone—ADRA2A—lymph node—skin cancer	0.000256	0.00213	CbGeAlD
Ziprasidone—Hyperhidrosis—Temozolomide—skin cancer	0.000255	0.000803	CcSEcCtD
Ziprasidone—Chest pain—Fluorouracil—skin cancer	0.000254	0.000799	CcSEcCtD
Ziprasidone—Myalgia—Fluorouracil—skin cancer	0.000254	0.000799	CcSEcCtD
Ziprasidone—Decreased appetite—Dactinomycin—skin cancer	0.000254	0.000799	CcSEcCtD
Ziprasidone—Fatigue—Dactinomycin—skin cancer	0.000252	0.000792	CcSEcCtD
Ziprasidone—Anorexia—Temozolomide—skin cancer	0.000252	0.000792	CcSEcCtD
Ziprasidone—Urticaria—Bleomycin—skin cancer	0.000249	0.000782	CcSEcCtD
Ziprasidone—Haemoglobin—Docetaxel—skin cancer	0.000248	0.000782	CcSEcCtD
Ziprasidone—Rhinitis—Docetaxel—skin cancer	0.000248	0.00078	CcSEcCtD
Ziprasidone—Body temperature increased—Bleomycin—skin cancer	0.000247	0.000779	CcSEcCtD
Ziprasidone—Haemorrhage—Docetaxel—skin cancer	0.000247	0.000778	CcSEcCtD
Ziprasidone—Hepatitis—Docetaxel—skin cancer	0.000247	0.000778	CcSEcCtD
Ziprasidone—Hypoaesthesia—Docetaxel—skin cancer	0.000246	0.000774	CcSEcCtD
Ziprasidone—Confusional state—Fluorouracil—skin cancer	0.000245	0.000772	CcSEcCtD
Ziprasidone—Pharyngitis—Docetaxel—skin cancer	0.000245	0.000772	CcSEcCtD
Ziprasidone—Urinary tract disorder—Docetaxel—skin cancer	0.000244	0.000768	CcSEcCtD
Ziprasidone—Oedema peripheral—Docetaxel—skin cancer	0.000243	0.000766	CcSEcCtD
Ziprasidone—Connective tissue disorder—Docetaxel—skin cancer	0.000243	0.000764	CcSEcCtD
Ziprasidone—Urethral disorder—Docetaxel—skin cancer	0.000242	0.000762	CcSEcCtD
Ziprasidone—Infection—Fluorouracil—skin cancer	0.000242	0.00076	CcSEcCtD
Ziprasidone—Feeling abnormal—Dactinomycin—skin cancer	0.000241	0.000757	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000241	0.000757	CcSEcCtD
Ziprasidone—Insomnia—Temozolomide—skin cancer	0.000239	0.000751	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000239	0.000751	CcSEcCtD
Ziprasidone—Nervous system disorder—Fluorouracil—skin cancer	0.000239	0.000751	CcSEcCtD
Ziprasidone—Thrombocytopenia—Fluorouracil—skin cancer	0.000238	0.00075	CcSEcCtD
Ziprasidone—Visual impairment—Docetaxel—skin cancer	0.000238	0.000749	CcSEcCtD
Ziprasidone—Tachycardia—Fluorouracil—skin cancer	0.000237	0.000747	CcSEcCtD
Ziprasidone—Paraesthesia—Temozolomide—skin cancer	0.000237	0.000746	CcSEcCtD
Ziprasidone—Dyspnoea—Temozolomide—skin cancer	0.000235	0.000741	CcSEcCtD
Ziprasidone—Somnolence—Temozolomide—skin cancer	0.000235	0.000739	CcSEcCtD
Ziprasidone—Dyspepsia—Temozolomide—skin cancer	0.000232	0.000731	CcSEcCtD
Ziprasidone—Anorexia—Fluorouracil—skin cancer	0.000232	0.00073	CcSEcCtD
Ziprasidone—Eye disorder—Docetaxel—skin cancer	0.000231	0.000727	CcSEcCtD
Ziprasidone—Abdominal pain—Dactinomycin—skin cancer	0.000231	0.000726	CcSEcCtD
Ziprasidone—Body temperature increased—Dactinomycin—skin cancer	0.000231	0.000726	CcSEcCtD
Ziprasidone—Hypersensitivity—Bleomycin—skin cancer	0.000231	0.000726	CcSEcCtD
Ziprasidone—Decreased appetite—Temozolomide—skin cancer	0.000229	0.000722	CcSEcCtD
Ziprasidone—Cardiac disorder—Docetaxel—skin cancer	0.000229	0.000722	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000228	0.000717	CcSEcCtD
Ziprasidone—Fatigue—Temozolomide—skin cancer	0.000228	0.000716	CcSEcCtD
Ziprasidone—Hypotension—Fluorouracil—skin cancer	0.000227	0.000715	CcSEcCtD
Ziprasidone—Constipation—Temozolomide—skin cancer	0.000226	0.00071	CcSEcCtD
Ziprasidone—Asthenia—Bleomycin—skin cancer	0.000225	0.000707	CcSEcCtD
Ziprasidone—Angiopathy—Docetaxel—skin cancer	0.000224	0.000706	CcSEcCtD
Ziprasidone—Immune system disorder—Docetaxel—skin cancer	0.000223	0.000702	CcSEcCtD
Ziprasidone—Mediastinal disorder—Docetaxel—skin cancer	0.000223	0.000701	CcSEcCtD
Ziprasidone—Chills—Docetaxel—skin cancer	0.000222	0.000698	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000222	0.000697	CcSEcCtD
Ziprasidone—Arrhythmia—Docetaxel—skin cancer	0.000221	0.000695	CcSEcCtD
Ziprasidone—Insomnia—Fluorouracil—skin cancer	0.00022	0.000692	CcSEcCtD
Ziprasidone—Paraesthesia—Fluorouracil—skin cancer	0.000218	0.000687	CcSEcCtD
Ziprasidone—Alopecia—Docetaxel—skin cancer	0.000218	0.000687	CcSEcCtD
Ziprasidone—Feeling abnormal—Temozolomide—skin cancer	0.000218	0.000685	CcSEcCtD
Ziprasidone—Dyspnoea—Fluorouracil—skin cancer	0.000217	0.000682	CcSEcCtD
Ziprasidone—Mental disorder—Docetaxel—skin cancer	0.000216	0.000681	CcSEcCtD
Ziprasidone—Somnolence—Fluorouracil—skin cancer	0.000216	0.000681	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Temozolomide—skin cancer	0.000216	0.000679	CcSEcCtD
Ziprasidone—Malnutrition—Docetaxel—skin cancer	0.000215	0.000677	CcSEcCtD
Ziprasidone—Erythema—Docetaxel—skin cancer	0.000215	0.000677	CcSEcCtD
Ziprasidone—Hypersensitivity—Dactinomycin—skin cancer	0.000215	0.000677	CcSEcCtD
Ziprasidone—Dyspepsia—Fluorouracil—skin cancer	0.000214	0.000674	CcSEcCtD
Ziprasidone—Decreased appetite—Fluorouracil—skin cancer	0.000211	0.000665	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00021	0.000661	CcSEcCtD
Ziprasidone—Urticaria—Temozolomide—skin cancer	0.00021	0.00066	CcSEcCtD
Ziprasidone—Asthenia—Dactinomycin—skin cancer	0.000209	0.000659	CcSEcCtD
Ziprasidone—Abdominal pain—Temozolomide—skin cancer	0.000209	0.000657	CcSEcCtD
Ziprasidone—Body temperature increased—Temozolomide—skin cancer	0.000209	0.000657	CcSEcCtD
Ziprasidone—Back pain—Docetaxel—skin cancer	0.000208	0.000655	CcSEcCtD
Ziprasidone—Muscle spasms—Docetaxel—skin cancer	0.000207	0.000651	CcSEcCtD
Ziprasidone—Feeling abnormal—Fluorouracil—skin cancer	0.0002	0.000631	CcSEcCtD
Ziprasidone—Diarrhoea—Dactinomycin—skin cancer	0.0002	0.000628	CcSEcCtD
Ziprasidone—Vomiting—Bleomycin—skin cancer	0.000199	0.000626	CcSEcCtD
Ziprasidone—Anaemia—Docetaxel—skin cancer	0.000199	0.000626	CcSEcCtD
Ziprasidone—Rash—Bleomycin—skin cancer	0.000197	0.000621	CcSEcCtD
Ziprasidone—Dermatitis—Bleomycin—skin cancer	0.000197	0.00062	CcSEcCtD
Ziprasidone—Hypersensitivity—Temozolomide—skin cancer	0.000194	0.000612	CcSEcCtD
Ziprasidone—Urticaria—Fluorouracil—skin cancer	0.000193	0.000608	CcSEcCtD
Ziprasidone—Syncope—Docetaxel—skin cancer	0.000193	0.000607	CcSEcCtD
Ziprasidone—Leukopenia—Docetaxel—skin cancer	0.000193	0.000606	CcSEcCtD
Ziprasidone—Body temperature increased—Fluorouracil—skin cancer	0.000192	0.000605	CcSEcCtD
Ziprasidone—Palpitations—Docetaxel—skin cancer	0.00019	0.000598	CcSEcCtD
Ziprasidone—Asthenia—Temozolomide—skin cancer	0.000189	0.000596	CcSEcCtD
Ziprasidone—Loss of consciousness—Docetaxel—skin cancer	0.000189	0.000595	CcSEcCtD
Ziprasidone—Cough—Docetaxel—skin cancer	0.000188	0.000591	CcSEcCtD
Ziprasidone—Nausea—Bleomycin—skin cancer	0.000186	0.000585	CcSEcCtD
Ziprasidone—Hypertension—Docetaxel—skin cancer	0.000186	0.000584	CcSEcCtD
Ziprasidone—Vomiting—Dactinomycin—skin cancer	0.000186	0.000584	CcSEcCtD
Ziprasidone—Rash—Dactinomycin—skin cancer	0.000184	0.000579	CcSEcCtD
Ziprasidone—Arthralgia—Docetaxel—skin cancer	0.000183	0.000576	CcSEcCtD
Ziprasidone—Myalgia—Docetaxel—skin cancer	0.000183	0.000576	CcSEcCtD
Ziprasidone—Chest pain—Docetaxel—skin cancer	0.000183	0.000576	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000182	0.000572	CcSEcCtD
Ziprasidone—Diarrhoea—Temozolomide—skin cancer	0.000181	0.000568	CcSEcCtD
Ziprasidone—Hypersensitivity—Fluorouracil—skin cancer	0.000179	0.000564	CcSEcCtD
Ziprasidone—Dry mouth—Docetaxel—skin cancer	0.000179	0.000564	CcSEcCtD
Ziprasidone—Confusional state—Docetaxel—skin cancer	0.000177	0.000557	CcSEcCtD
Ziprasidone—Dizziness—Temozolomide—skin cancer	0.000175	0.000549	CcSEcCtD
Ziprasidone—Infection—Docetaxel—skin cancer	0.000174	0.000549	CcSEcCtD
Ziprasidone—Nausea—Dactinomycin—skin cancer	0.000173	0.000546	CcSEcCtD
Ziprasidone—Shock—Docetaxel—skin cancer	0.000173	0.000544	CcSEcCtD
Ziprasidone—Nervous system disorder—Docetaxel—skin cancer	0.000172	0.000542	CcSEcCtD
Ziprasidone—Thrombocytopenia—Docetaxel—skin cancer	0.000172	0.000541	CcSEcCtD
Ziprasidone—Tachycardia—Docetaxel—skin cancer	0.000171	0.000539	CcSEcCtD
Ziprasidone—Skin disorder—Docetaxel—skin cancer	0.000171	0.000537	CcSEcCtD
Ziprasidone—Vomiting—Temozolomide—skin cancer	0.000168	0.000528	CcSEcCtD
Ziprasidone—Anorexia—Docetaxel—skin cancer	0.000167	0.000527	CcSEcCtD
Ziprasidone—Rash—Temozolomide—skin cancer	0.000166	0.000524	CcSEcCtD
Ziprasidone—Diarrhoea—Fluorouracil—skin cancer	0.000166	0.000524	CcSEcCtD
Ziprasidone—Dermatitis—Temozolomide—skin cancer	0.000166	0.000523	CcSEcCtD
Ziprasidone—Headache—Temozolomide—skin cancer	0.000165	0.00052	CcSEcCtD
Ziprasidone—Hypotension—Docetaxel—skin cancer	0.000164	0.000516	CcSEcCtD
Ziprasidone—Dizziness—Fluorouracil—skin cancer	0.000161	0.000506	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00016	0.000503	CcSEcCtD
Ziprasidone—Insomnia—Docetaxel—skin cancer	0.000159	0.0005	CcSEcCtD
Ziprasidone—Paraesthesia—Docetaxel—skin cancer	0.000158	0.000496	CcSEcCtD
Ziprasidone—Nausea—Temozolomide—skin cancer	0.000157	0.000493	CcSEcCtD
Ziprasidone—Dyspnoea—Docetaxel—skin cancer	0.000157	0.000493	CcSEcCtD
Ziprasidone—Somnolence—Docetaxel—skin cancer	0.000156	0.000491	CcSEcCtD
Ziprasidone—Vomiting—Fluorouracil—skin cancer	0.000155	0.000487	CcSEcCtD
Ziprasidone—Dyspepsia—Docetaxel—skin cancer	0.000155	0.000486	CcSEcCtD
Ziprasidone—Rash—Fluorouracil—skin cancer	0.000153	0.000483	CcSEcCtD
Ziprasidone—Dermatitis—Fluorouracil—skin cancer	0.000153	0.000482	CcSEcCtD
Ziprasidone—Decreased appetite—Docetaxel—skin cancer	0.000153	0.00048	CcSEcCtD
Ziprasidone—Headache—Fluorouracil—skin cancer	0.000152	0.00048	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Docetaxel—skin cancer	0.000152	0.000477	CcSEcCtD
Ziprasidone—Fatigue—Docetaxel—skin cancer	0.000151	0.000476	CcSEcCtD
Ziprasidone—Constipation—Docetaxel—skin cancer	0.00015	0.000472	CcSEcCtD
Ziprasidone—Feeling abnormal—Docetaxel—skin cancer	0.000145	0.000455	CcSEcCtD
Ziprasidone—Nausea—Fluorouracil—skin cancer	0.000144	0.000455	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Docetaxel—skin cancer	0.000144	0.000452	CcSEcCtD
Ziprasidone—Abdominal pain—Docetaxel—skin cancer	0.000139	0.000437	CcSEcCtD
Ziprasidone—Body temperature increased—Docetaxel—skin cancer	0.000139	0.000437	CcSEcCtD
Ziprasidone—Hypersensitivity—Docetaxel—skin cancer	0.000129	0.000407	CcSEcCtD
Ziprasidone—Asthenia—Docetaxel—skin cancer	0.000126	0.000396	CcSEcCtD
Ziprasidone—Diarrhoea—Docetaxel—skin cancer	0.00012	0.000378	CcSEcCtD
Ziprasidone—Dizziness—Docetaxel—skin cancer	0.000116	0.000365	CcSEcCtD
Ziprasidone—Vomiting—Docetaxel—skin cancer	0.000112	0.000351	CcSEcCtD
Ziprasidone—Rash—Docetaxel—skin cancer	0.000111	0.000348	CcSEcCtD
Ziprasidone—Dermatitis—Docetaxel—skin cancer	0.000111	0.000348	CcSEcCtD
Ziprasidone—Headache—Docetaxel—skin cancer	0.00011	0.000346	CcSEcCtD
Ziprasidone—Nausea—Docetaxel—skin cancer	0.000104	0.000328	CcSEcCtD
Ziprasidone—DRD4—Signaling Pathways—BRAF—skin cancer	1.28e-05	0.000187	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—BRAF—skin cancer	1.26e-05	0.000185	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—ERCC2—skin cancer	1.25e-05	0.000184	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TERT—skin cancer	1.25e-05	0.000183	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TERT—skin cancer	1.24e-05	0.000182	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—KRAS—skin cancer	1.24e-05	0.000182	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—NRAS—skin cancer	1.23e-05	0.00018	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—NRAS—skin cancer	1.22e-05	0.000179	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—KRAS—skin cancer	1.22e-05	0.000179	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—KRAS—skin cancer	1.22e-05	0.000179	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—KRAS—skin cancer	1.21e-05	0.000178	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TERT—skin cancer	1.21e-05	0.000177	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—NRAS—skin cancer	1.21e-05	0.000177	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—BRAF—skin cancer	1.21e-05	0.000177	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ENO2—skin cancer	1.19e-05	0.000175	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TERT—skin cancer	1.19e-05	0.000174	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—KRAS—skin cancer	1.19e-05	0.000174	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—KRAS—skin cancer	1.17e-05	0.000172	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—KRAS—skin cancer	1.15e-05	0.000169	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—BRAF—skin cancer	1.15e-05	0.000169	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ERCC2—skin cancer	1.15e-05	0.000168	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—BRAF—skin cancer	1.13e-05	0.000166	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—KRAS—skin cancer	1.1e-05	0.000162	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—TP53—skin cancer	1.1e-05	0.000162	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TERT—skin cancer	1.09e-05	0.000161	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.09e-05	0.00016	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—NRAS—skin cancer	1.09e-05	0.00016	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TERT—skin cancer	1.08e-05	0.000158	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TERT—skin cancer	1.07e-05	0.000158	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TERT—skin cancer	1.07e-05	0.000157	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TERT—skin cancer	1.07e-05	0.000157	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TERT—skin cancer	1.06e-05	0.000155	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—KRAS—skin cancer	1.06e-05	0.000155	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TERT—skin cancer	1.05e-05	0.000155	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—HRAS—skin cancer	1.05e-05	0.000155	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—KRAS—skin cancer	1.05e-05	0.000154	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.05e-05	0.000154	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.05e-05	0.000154	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—HRAS—skin cancer	1.04e-05	0.000153	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—KRAS—skin cancer	1.04e-05	0.000152	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—HRAS—skin cancer	1.04e-05	0.000152	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.03e-05	0.000151	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.02e-05	0.00015	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.02e-05	0.000149	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.01e-05	0.000148	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1e-05	0.000147	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL6—skin cancer	9.94e-06	0.000146	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—HRAS—skin cancer	9.93e-06	0.000146	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL6—skin cancer	9.93e-06	0.000146	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—BRAF—skin cancer	9.88e-06	0.000145	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL6—skin cancer	9.86e-06	0.000145	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—BRAF—skin cancer	9.82e-06	0.000144	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TERT—skin cancer	9.8e-06	0.000144	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—HRAS—skin cancer	9.8e-06	0.000144	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL6—skin cancer	9.66e-06	0.000142	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—BRAF—skin cancer	9.56e-06	0.00014	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PTGS2—skin cancer	9.51e-06	0.00014	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL6—skin cancer	9.5e-06	0.00014	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—BRAF—skin cancer	9.41e-06	0.000138	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—skin cancer	9.39e-06	0.000138	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—HRAS—skin cancer	9.38e-06	0.000138	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL6—skin cancer	9.38e-06	0.000138	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—KRAS—skin cancer	9.37e-06	0.000138	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—KRAS—skin cancer	9.35e-06	0.000137	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.29e-06	0.000137	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PTGS2—skin cancer	9.23e-06	0.000136	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—NRAS—skin cancer	9.22e-06	0.000136	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ENO2—skin cancer	9.17e-06	0.000135	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—NRAS—skin cancer	9.08e-06	0.000133	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—NRAS—skin cancer	9.06e-06	0.000133	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—KRAS—skin cancer	9.04e-06	0.000133	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—NRAS—skin cancer	9.03e-06	0.000133	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—NRAS—skin cancer	9e-06	0.000132	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—KRAS—skin cancer	9e-06	0.000132	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—HRAS—skin cancer	8.98e-06	0.000132	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL6—skin cancer	8.98e-06	0.000132	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—HRAS—skin cancer	8.94e-06	0.000131	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—NRAS—skin cancer	8.91e-06	0.000131	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—NRAS—skin cancer	8.89e-06	0.000131	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—HRAS—skin cancer	8.82e-06	0.00013	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—KRAS—skin cancer	8.75e-06	0.000129	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—BRAF—skin cancer	8.67e-06	0.000127	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—KRAS—skin cancer	8.61e-06	0.000127	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL6—skin cancer	8.59e-06	0.000126	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL6—skin cancer	8.56e-06	0.000126	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—BRAF—skin cancer	8.53e-06	0.000125	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—BRAF—skin cancer	8.51e-06	0.000125	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—BRAF—skin cancer	8.49e-06	0.000125	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—BRAF—skin cancer	8.46e-06	0.000124	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL6—skin cancer	8.44e-06	0.000124	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—NRAS—skin cancer	8.38e-06	0.000123	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—BRAF—skin cancer	8.38e-06	0.000123	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—NRAS—skin cancer	8.38e-06	0.000123	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—BRAF—skin cancer	8.35e-06	0.000123	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—NRAS—skin cancer	8.32e-06	0.000122	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—skin cancer	8.31e-06	0.000122	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—NRAS—skin cancer	8.26e-06	0.000121	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTGS2—skin cancer	8.17e-06	0.00012	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ERCC2—skin cancer	8.15e-06	0.00012	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—NRAS—skin cancer	8.15e-06	0.00012	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—NRAS—skin cancer	8.02e-06	0.000118	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—HRAS—skin cancer	7.96e-06	0.000117	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—HRAS—skin cancer	7.95e-06	0.000117	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—KRAS—skin cancer	7.94e-06	0.000117	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—NRAS—skin cancer	7.91e-06	0.000116	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—KRAS—skin cancer	7.81e-06	0.000115	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—KRAS—skin cancer	7.8e-06	0.000115	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—KRAS—skin cancer	7.77e-06	0.000114	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—BRAF—skin cancer	7.76e-06	0.000114	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—KRAS—skin cancer	7.75e-06	0.000114	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—HRAS—skin cancer	7.69e-06	0.000113	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—KRAS—skin cancer	7.67e-06	0.000113	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—KRAS—skin cancer	7.65e-06	0.000112	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—HRAS—skin cancer	7.65e-06	0.000112	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL6—skin cancer	7.62e-06	0.000112	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL6—skin cancer	7.61e-06	0.000112	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—NRAS—skin cancer	7.57e-06	0.000111	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTGS2—skin cancer	7.5e-06	0.00011	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—HRAS—skin cancer	7.44e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL6—skin cancer	7.36e-06	0.000108	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—HRAS—skin cancer	7.32e-06	0.000108	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—skin cancer	7.32e-06	0.000108	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—NRAS—skin cancer	7.22e-06	0.000106	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KRAS—skin cancer	7.22e-06	0.000106	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KRAS—skin cancer	7.21e-06	0.000106	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KRAS—skin cancer	7.16e-06	0.000105	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—NRAS—skin cancer	7.12e-06	0.000105	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—skin cancer	7.12e-06	0.000105	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—KRAS—skin cancer	7.11e-06	0.000104	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KRAS—skin cancer	7.01e-06	0.000103	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—skin cancer	7.01e-06	0.000103	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ERCC2—skin cancer	6.9e-06	0.000101	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KRAS—skin cancer	6.9e-06	0.000101	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—skin cancer	6.87e-06	0.000101	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KRAS—skin cancer	6.81e-06	0.0001	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—HRAS—skin cancer	6.75e-06	9.91e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—HRAS—skin cancer	6.64e-06	9.75e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—HRAS—skin cancer	6.63e-06	9.73e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—HRAS—skin cancer	6.6e-06	9.7e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—HRAS—skin cancer	6.58e-06	9.67e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—HRAS—skin cancer	6.52e-06	9.58e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KRAS—skin cancer	6.52e-06	9.58e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—HRAS—skin cancer	6.5e-06	9.55e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—skin cancer	6.46e-06	9.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NRAS—skin cancer	6.43e-06	9.44e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—skin cancer	6.41e-06	9.42e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—skin cancer	6.41e-06	9.41e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—skin cancer	6.37e-06	9.35e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—skin cancer	6.36e-06	9.34e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—skin cancer	6.34e-06	9.32e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—skin cancer	6.32e-06	9.29e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—skin cancer	6.3e-06	9.26e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—skin cancer	6.24e-06	9.17e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—skin cancer	6.23e-06	9.16e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—skin cancer	6.22e-06	9.14e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KRAS—skin cancer	6.21e-06	9.13e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NRAS—skin cancer	6.21e-06	9.12e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NRAS—skin cancer	6.17e-06	9.07e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HRAS—skin cancer	6.13e-06	9.01e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—skin cancer	6.13e-06	9.01e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—skin cancer	6.13e-06	9e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HRAS—skin cancer	6.13e-06	9e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HRAS—skin cancer	6.09e-06	8.94e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—skin cancer	6.05e-06	8.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HRAS—skin cancer	6.04e-06	8.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NRAS—skin cancer	6.01e-06	8.82e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—skin cancer	5.96e-06	8.76e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NRAS—skin cancer	5.91e-06	8.68e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—skin cancer	5.87e-06	8.62e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—skin cancer	5.87e-06	8.62e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—skin cancer	5.86e-06	8.61e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—skin cancer	5.83e-06	8.56e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—skin cancer	5.79e-06	8.51e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—skin cancer	5.79e-06	8.5e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—skin cancer	5.78e-06	8.49e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—skin cancer	5.7e-06	8.38e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—skin cancer	5.61e-06	8.25e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—skin cancer	5.54e-06	8.14e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—skin cancer	5.54e-06	8.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—skin cancer	5.53e-06	8.13e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—skin cancer	5.52e-06	8.11e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NRAS—skin cancer	5.45e-06	8.01e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—skin cancer	5.45e-06	8e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NRAS—skin cancer	5.36e-06	7.88e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NRAS—skin cancer	5.35e-06	7.86e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—skin cancer	5.34e-06	7.85e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NRAS—skin cancer	5.33e-06	7.83e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ERCC2—skin cancer	5.33e-06	7.83e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NRAS—skin cancer	5.32e-06	7.81e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—skin cancer	5.31e-06	7.81e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—skin cancer	5.3e-06	7.79e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—skin cancer	5.28e-06	7.76e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NRAS—skin cancer	5.26e-06	7.73e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NRAS—skin cancer	5.25e-06	7.71e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—skin cancer	5.21e-06	7.65e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—skin cancer	5.17e-06	7.59e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—skin cancer	5.09e-06	7.47e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—skin cancer	5.05e-06	7.42e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—skin cancer	4.99e-06	7.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—skin cancer	4.92e-06	7.22e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—skin cancer	4.89e-06	7.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NRAS—skin cancer	4.88e-06	7.17e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—skin cancer	4.75e-06	6.97e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—skin cancer	4.72e-06	6.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—skin cancer	4.7e-06	6.91e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—skin cancer	4.69e-06	6.89e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—skin cancer	4.61e-06	6.78e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—skin cancer	4.6e-06	6.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—skin cancer	4.59e-06	6.75e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—skin cancer	4.59e-06	6.74e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—skin cancer	4.58e-06	6.72e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—skin cancer	4.54e-06	6.67e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—skin cancer	4.53e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—skin cancer	4.52e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—skin cancer	4.52e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—skin cancer	4.52e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—skin cancer	4.5e-06	6.61e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—skin cancer	4.39e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—skin cancer	4.35e-06	6.38e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—skin cancer	4.32e-06	6.35e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—skin cancer	4.32e-06	6.35e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—skin cancer	4.21e-06	6.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—skin cancer	4.2e-06	6.17e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—skin cancer	4.17e-06	6.12e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—skin cancer	4.14e-06	6.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—skin cancer	4.14e-06	6.08e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—skin cancer	4.1e-06	6.03e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—skin cancer	4.09e-06	6.01e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—skin cancer	4.08e-06	5.99e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—skin cancer	4.07e-06	5.97e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—skin cancer	4.03e-06	5.92e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—skin cancer	4.02e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—skin cancer	3.99e-06	5.86e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—skin cancer	3.92e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—skin cancer	3.91e-06	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—skin cancer	3.9e-06	5.73e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—skin cancer	3.89e-06	5.71e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—skin cancer	3.85e-06	5.66e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—skin cancer	3.84e-06	5.64e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—skin cancer	3.82e-06	5.61e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—skin cancer	3.75e-06	5.52e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—skin cancer	3.75e-06	5.5e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—skin cancer	3.73e-06	5.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—skin cancer	3.73e-06	5.48e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—skin cancer	3.72e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—skin cancer	3.69e-06	5.42e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—skin cancer	3.68e-06	5.4e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—skin cancer	3.57e-06	5.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—skin cancer	3.42e-06	5.02e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—skin cancer	3.19e-06	4.69e-05	CbGpPWpGaD
